PolyPid Announces Significant SHIELD II Trial Outcomes
PolyPid Ltd. (NASDAQ: PYPD), a pioneering biopharma company focused on enhancing surgical outcomes, has recently unveiled that Dr. Shmuel Sharoni will showcase the topline results from its Phase 3 SHIELD II trial at the upcoming American College of Surgeons (ACS) Clinical Congress. This presentation is a notable opportunity for PolyPid to highlight their innovative strategies aimed at reducing surgical complications in abdominal colorectal surgeries.
Presentation Highlights
During the conference scheduled to take place in Chicago, Dr. Sharoni's talk will be focused on the efficacy of D-PLEX???, PolyPid's treatment designed to prevent surgical site infections. The presentation will take place on Sunday, October 5, 2025, at 11:30 AM CT during a session dedicated to high-impact clinical trials.
Conference Details
The ACS Clinical Congress will occur from October 4-7, 2025, at McCormick Place in Chicago. Attendees will gain insights into the latest research and advancements in surgical care through various presentations, including those from leading figures in the field such as Dr. Sharoni.
Understanding the SHIELD II Trial
The SHIELD II trial is a groundbreaking, multinational, randomized, and double-blind study designed to assess the efficiency of D-PLEX??? alongside standard surgical care. The trial successfully met its primary and all key secondary efficacy endpoints, demonstrating a remarkable 38% reduction in combined incidents of surgical site infections, reinterventions, or mortality.
Trial Outcomes
Moreover, the data indicates a notable 58% decline in surgical site infections among patients receiving the D-PLEX??? treatment. These findings are monumental as they pave the way for safer surgical practices and improved recovery outcomes for patients undergoing colorectal surgeries.
About PolyPid and D-PLEX???
PolyPid Ltd. is committed to transforming surgical protocols with its innovative PLEX technology that allows for locally administered therapeutics with controlled and prolonged release. D-PLEX???, the company's flagship product, aims to deliver localized medication effectively, thus optimizing treatment durations and improving clinical outcomes in surgical settings.
Future Prospects
Looking ahead, PolyPid plans to submit a New Drug Application (NDA) for D-PLEX??? in early 2026, marking a significant milestone in their journey to elevate surgical care standards. The company's pipeline extends beyond surgical applications, delving into therapeutic solutions for areas such as oncology, obesity, and diabetes.
Contact Information
The management team at PolyPid will be present at the ACS Clinical Congress and welcomes inquiries regarding their groundbreaking work. For scheduling meetings or further inquiries, interested parties can email IR@Polypid.com.
Frequently Asked Questions
What is PolyPid's focus in the biopharma industry?
PolyPid Ltd. specializes in developing surgical therapeutics that enhance patient outcomes through innovative drug delivery systems.
What are the results of the SHIELD II trial?
The SHIELD II trial demonstrated a 38% reduction in surgical site infections and a 58% decrease in overall complications when using D-PLEX??? alongside standard care.
When will PolyPid submit their NDA for D-PLEX????
PolyPid plans to submit their New Drug Application for D-PLEX??? in early 2026.
Who is presenting the results of the SHIELD II trial?
Dr. Shmuel Sharoni will be presenting the trial results at the ACS Clinical Congress in October 2025.
Where can I learn more about PolyPid?
For more information, you can visit http://www.polypid.com.
